<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181008</url>
  </required_header>
  <id_info>
    <org_study_id>126328</org_study_id>
    <nct_id>NCT04181008</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Venkata Yellepeddi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, open-label study of the plasma pharmacokinetics of amiloride
      nasal spray at three different doses in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical study, we will evaluate the plasma pharmacokinetics of amiloride nasal spray
      in healthy volunteers at three different doses. The data obtained from this study will
      provide us with pharmacokinetic information that will help develop dosing regimens for future
      clinical efficacy studies in anxiety patients. Currently, there is no information on the
      bioavailability and pharmacokinetics of amiloride in humans after intranasal administration.
      All participants will be allowed to self-administer amiloride nasal spray at 0.2, 0.4, and
      0.6 mg doses of amiloride. A series of timed blood samples (0,10, 15, 30, 60 minutes, and 4,
      6, 8, 12 and 24 hours,1mL each time point) will be collected.

      Primary objectives:

        1. To evaluate the pharmacokinetics of amiloride nasal spray at three different doses 0.2,
           0.4, and 0.6 mg in healthy human volunteers.

        2. To calculate the following pharmacokinetic parameters after intranasal administration of
           amiloride: time to reach maximum plasma concentration (Tmax), maximum plasma
           concentration (Cmax), area under the curve (AUC), the volume of distribution (Vd) and
           clearance (CL).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>amiloride plasma concentration</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Amiloride Nasal Spray</description>
    <arm_group_label>0.2 mg</arm_group_label>
    <other_name>Midamor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Amiloride Nasal Spray</description>
    <arm_group_label>0.4 mg</arm_group_label>
    <other_name>Midamor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Amiloride Nasal Spray</description>
    <arm_group_label>0.6 mg</arm_group_label>
    <other_name>Midamor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18 to 30 years of age.

          -  Females between 18 to 30 years of age.

          -  Provide written informed consent and authorization.

          -  Study participants must be able to complete consent, all study evaluations, olfactory
             testing, and study-related health questionnaires written in the English language.

        Exclusion Criteria:

          -  History of chronic drug, or narcotic abuse.

          -  Chronic use of tranquilizers, sedatives, aspirin, antibiotics, or other medications.

          -  Non-English speaking / English translation services required

          -  Unwilling or unable to provide informed, written consent.

          -  History or presence of major organ dysfunction.

          -  History of malignancy, stroke, or diabetes; cardiac, renal, liver, or severe
             gastrointestinal disease; or other serious illness.

          -  History of conditions which might contraindicate or require caution be used in the
             administration of amiloride including hyperkalemia with elevated serum potassium
             levels (greater than 5.5 mEq per liter), currently receiving other
             potassium-conserving agents such as spironolactone or triamterene, currently receiving
             potassium supplementation in the form of medication, potassium-containing salt
             substitutes or a potassium-rich diet, history or diagnosis of hypersensitivity to
             Amiloride.

          -  Subjects with abnormal kidney function tests [estimated glomerular filtration (eGFR) -
             &lt; 60, and albumin to creatinine ratio (ACR) - &gt; 30]

          -  Female subjects who are pregnant or nursing at the time of screening.

          -  Subjects who underwent any kind of surgery of nose and septum within the past one
             year.

          -  Subjects diagnosed with chronic rhinosinusitis.

          -  Treatment with any other investigational drug during the 30 days prior to enrollment
             into the study.

          -  Subjects who smoke, have a history of smoking or use nicotine-containing products.

          -  Subjects who have donated blood within 30 days prior to study entry, including that
             withdrawn during the conduct of any other clinical study.

          -  Subjects presenting with acute illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Venkata K Yellepeddi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Venkata K Yellepeddi, PhD</last_name>
    <phone>801-213-0701</phone>
    <email>venkata.yellepeddi@hsc.utah.edu</email>
  </overall_contact>
  <link>
    <url>https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0cc2d44-436a-47e8-a890-589882fff4c4</url>
    <description>Amiloride Hydrochloride, Drug Label Information</description>
  </link>
  <link>
    <url>https://www.janssen.com/janssen-announces-us-fda-approval-spravato-esketamine-ciii-nasal-spray-adults-treatment-resistant</url>
    <description>FDA Approval of SPRAVATOâ„¢ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression</description>
  </link>
  <reference>
    <citation>Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989 Nov 2;321(18):1209-14.</citation>
    <PMID>2797086</PMID>
  </reference>
  <reference>
    <citation>Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J, Zhang H, Smith SM, Pickering RP, Huang B, Hasin DS. Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2016 Jan;73(1):39-47. doi: 10.1001/jamapsychiatry.2015.2132.</citation>
    <PMID>26580136</PMID>
  </reference>
  <reference>
    <citation>Meuret AE, Rosenfield D, Wilhelm FH, Zhou E, Conrad A, Ritz T, Roth WT. Do unexpected panic attacks occur spontaneously? Biol Psychiatry. 2011 Nov 15;70(10):985-91. doi: 10.1016/j.biopsych.2011.05.027. Epub 2011 Jul 23.</citation>
    <PMID>21783179</PMID>
  </reference>
  <reference>
    <citation>Maddock RJ, Buonocore MH, Miller AR, Yoon JH, Soosman SK, Unruh AM. Abnormal activity-dependent brain lactate and glutamate+glutamine responses in panic disorder. Biol Psychiatry. 2013 Jun 1;73(11):1111-9. doi: 10.1016/j.biopsych.2012.12.015. Epub 2013 Jan 17.</citation>
    <PMID>23332354</PMID>
  </reference>
  <reference>
    <citation>Battaglia M, Pesenti-Gritti P, Medland SE, Ogliari A, Tambs K, Spatola CA. A genetically informed study of the association between childhood separation anxiety, sensitivity to CO(2), panic disorder, and the effect of childhood parental loss. Arch Gen Psychiatry. 2009 Jan;66(1):64-71. doi: 10.1001/archgenpsychiatry.2008.513.</citation>
    <PMID>19124689</PMID>
  </reference>
  <reference>
    <citation>Spatola CA, Scaini S, Pesenti-Gritti P, Medland SE, Moruzzi S, Ogliari A, Tambs K, Battaglia M. Gene-environment interactions in panic disorder and COâ‚‚ sensitivity: Effects of events occurring early in life. Am J Med Genet B Neuropsychiatr Genet. 2011 Jan;156B(1):79-88. doi: 10.1002/ajmg.b.31144. Epub 2010 Nov 30.</citation>
    <PMID>21184587</PMID>
  </reference>
  <reference>
    <citation>D'Amato FR, Zanettini C, Lampis V, Coccurello R, Pascucci T, Ventura R, Puglisi-Allegra S, Spatola CA, Pesenti-Gritti P, Oddi D, Moles A, Battaglia M. Unstable maternal environment, separation anxiety, and heightened CO2 sensitivity induced by gene-by-environment interplay. PLoS One. 2011 Apr 8;6(4):e18637. doi: 10.1371/journal.pone.0018637.</citation>
    <PMID>21494633</PMID>
  </reference>
  <reference>
    <citation>Cittaro D, Lampis V, Luchetti A, Coccurello R, Guffanti A, Felsani A, Moles A, Stupka E, D' Amato FR, Battaglia M. Histone Modifications in a Mouse Model of Early Adversities and Panic Disorder: Role for Asic1 and Neurodevelopmental Genes. Sci Rep. 2016 Apr 28;6:25131. doi: 10.1038/srep25131.</citation>
    <PMID>27121911</PMID>
  </reference>
  <reference>
    <citation>Giannese F, Luchetti A, Barbiera G, Lampis V, Zanettini C, Knudsen GP, Scaini S, Lazarevic D, Cittaro D, D'Amato FR, Battaglia M. Conserved DNA Methylation Signatures in Early Maternal Separation and in Twins Discordant for CO(2) Sensitivity. Sci Rep. 2018 Feb 2;8(1):2258. doi: 10.1038/s41598-018-20457-3.</citation>
    <PMID>29396481</PMID>
  </reference>
  <reference>
    <citation>Smoller JW, Gallagher PJ, Duncan LE, McGrath LM, Haddad SA, Holmes AJ, Wolf AB, Hilker S, Block SR, Weill S, Young S, Choi EY, Rosenbaum JF, Biederman J, Faraone SV, Roffman JL, Manfro GG, Blaya C, Hirshfeld-Becker DR, Stein MB, Van Ameringen M, Tolin DF, Otto MW, Pollack MH, Simon NM, Buckner RL, OngÃ¼r D, Cohen BM. The human ortholog of acid-sensing ion channel gene ASIC1a is associated with panic disorder and amygdala structure and function. Biol Psychiatry. 2014 Dec 1;76(11):902-10. doi: 10.1016/j.biopsych.2013.12.018. Epub 2014 Jan 18.</citation>
    <PMID>24529281</PMID>
  </reference>
  <reference>
    <citation>Battaglia M, Rossignol O, Bachand K, D'Amato FR, Koninck Y. Amiloride modulation of carbon dioxide hypersensitivity and thermal nociceptive hypersensitivity induced by interference with early maternal environment. J Psychopharmacol. 2019 Jan;33(1):101-108. doi: 10.1177/0269881118784872. Epub 2018 Jul 3.</citation>
    <PMID>29968500</PMID>
  </reference>
  <reference>
    <citation>Chapman CD, Frey WH 2nd, Craft S, Danielyan L, Hallschmid M, SchiÃ¶th HB, Benedict C. Intranasal treatment of central nervous system dysfunction in humans. Pharm Res. 2013 Oct;30(10):2475-84. doi: 10.1007/s11095-012-0915-1. Epub 2012 Nov 8. Review.</citation>
    <PMID>23135822</PMID>
  </reference>
  <reference>
    <citation>Yellepeddi VK. Stability of extemporaneously prepared preservative-free prochlorperazine nasal spray. Am J Health Syst Pharm. 2018 Jan 1;75(1):e28-e35. doi: 10.2146/ajhp160531.</citation>
    <PMID>29273610</PMID>
  </reference>
  <reference>
    <citation>Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. Aerosolized amiloride as treatment of cystic fibrosis lung disease: a pilot study. Adv Exp Med Biol. 1991;290:119-28; discussion 129-32.</citation>
    <PMID>1950741</PMID>
  </reference>
  <reference>
    <citation>Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, Edwards LJ, Helms RW, Boucher RC. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med. 1990 Apr 26;322(17):1189-94.</citation>
    <PMID>2157983</PMID>
  </reference>
  <reference>
    <citation>Noone PG, Regnis JA, Liu X, Brouwer KL, Robinson M, Edwards L, Knowles MR. Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest. 1997 Nov 5;112(5):1283-90.</citation>
    <PMID>9367469</PMID>
  </reference>
  <reference>
    <citation>Olivier KN, Bennett WD, Hohneker KW, Zeman KL, Edwards LJ, Boucher RC, Knowles MR. Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults. Am J Respir Crit Care Med. 1996 Jul;154(1):217-23.</citation>
    <PMID>8680683</PMID>
  </reference>
  <reference>
    <citation>Sood N, Bennett WD, Zeman K, Brown J, Foy C, Boucher RC, Knowles MR. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med. 2003 Jan 15;167(2):158-63. Epub 2002 Oct 31.</citation>
    <PMID>12411282</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Venkata Yellepeddi</investigator_full_name>
    <investigator_title>Associate Professor, Division of Clinical Pharmacology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

